Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Vanguard Total World Stock Index Fund ETF trades at $155.9. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | VT | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $812.27 | $159.35 |
52-Week Low | $545.46 | $128.41 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Vanguard Total World Stock ETF (VT) trades at $154.29, down 0.32% on the day, with technical indicators showing a bearish bias despite neutral oscillators. The ETF provides diversified global equity exposure with over 10,000 stocks across developed and emerging markets. Recent news highlights institutional interest, with Alta Advisers Ltd increasing its position by 18.5% in Q1 2026 (SEC filing, 2026-07-21).
VT offers broad global diversification with a low 0.06% expense ratio, appealing for long-term investors seeking worldwide market exposure. Key risks include global economic volatility and currency fluctuations. The bearish technical signals suggest near-term pressure, but the fund's comprehensive coverage provides stability for portfolio construction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
